Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Construction is now underway with the facility scheduled to be operational by 2025
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Mandaviya felicitated voluntary blood donors and states/UTs that have done exemplary work
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Enriched with eight ayurvedic active ingredients like Ashwagandha, Shilajit, Shatavari, and Pippali, Be One works holistically to provide energy, build immunity and enable a healthy body and mind
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
The two-day meeting in the city was organized in collaboration with the University of Birmingham, Christian Medical College Ludhiana, and Birmingham Clinical Trials Unit
Funds raised will be used to develop technology and foster healthcare partnerships
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Transformation to pure-play Innovative Medicines company nears completion
NATCO estimates the current market size of CTPR containing products in India to be over Rs. 2,000 crore.
India's healthcare system has shown great efficiency not only in providing diagnostic and management facilities but also in minimizing mortality and maximizing recovery
The companies will leverage their respective proprietary technology platforms
The company has received payment towards completion of sale of the first tranche from Sekhmet Pharmaventures Private Limited.
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
Subscribe To Our Newsletter & Stay Updated
